Venous InsufficiencyNCT00270972
The Evaluation of OrCel for the Treatment of Venous Ulcers
A study testing Bilayered Cellular Matrix (OrCel) in people with Venous Insufficiency and Leg Ulcer, run by Ortec International at 10 sites in United States.
Trial summary
This study was designed to confirm the clinical benefits and safety of OrCel in the treatment of venous ulcers. OrCel and standard care are compared to standard care alone. Standard care consists of currently accepted compression therapy. Patients are treated for 12 weeks. Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Venous Insufficiency, Leg Ulcer
- What is being tested?
- Bilayered Cellular Matrix (OrCel)
- Type of treatment
- Medical device
- How many people
- 60 participants
- Where
- 10 sitesUnited States
- Study dates
- Sep 2005to not given
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Any race, between 18 and 85 years of age
- Male or female
- Chronic venous insufficiency
- Ulcer size between 2 and 20 sq cm, inclusive
- Ulcer present for at least one month
- ABI >0.7
Who cannot join
- Decrease in wound size >35% during Screening Phase
- Infection at ulcer site
- Uncontrolled diabetes mellitus
- Malnutrition
- Previous treatment with excluded medications
Trial locations and contacts
10 sites in 1 country.
10 sites in 1 country
United States10 sites
Southside Hospital
Bay Shore, New York, 11706
Eden Podiatry Group
Castro Valley, California, 94546
Hyperbaric and Wound Care Associates
Milwaukee, Wisconsin, 53215
Baptist Medical Center South
Montgomery, Alabama, 36116
St Luke's Roosevelt
New York, New York, 10025
Associated Foot and Ankle Specialists
Phoenix, Arizona, 85015
PPH Center for Wound Care and Hyperbaric Medicine
Poway, California, 92064
Center for Advanced Wound Care
Reading, Pennsylvania, 19601
Wound Healing Center
Terre Haute, Indiana, 47807
Warren General Hospital
Warren, Pennsylvania, 16365
About this study
Official title: A Confirmatory Study to Evaluate the Safety and Efficacy of Cryopreserved Bilayered Cellular Matrix (ORCEL) for the Treatment of Venous Ulcers
This study was designed to confirm the clinical benefits and safety of OrCel in the treatment of venous ulcers. OrCel and standard care are compared to standard care alone. Standard care consists of currently accepted compression therapy.
Patients are treated for 12 weeks. Patients with healed ulcers are followed for an additional 12 weeks to assess durability of the healed wound.
- Conditions
- Venous Insufficiency, Leg Ulcer
- Being tested
- Bilayered Cellular Matrix (OrCel)
- Keywords
- Venous leg ulcer, Venous insufficiency, OrCel
- Medical subject headings
- Venous Insufficiency, Leg Ulcer, Varicose Ulcer
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Bilayered Cellular Matrix (OrCel)Device
What is being measured
The primary outcome is the main question the study is designed to answer.
Investigator Assessment of wound healing
Secondary outcomes (2)
Planimetric assessment of wound healing
Photographic assessment of wound healing
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Dec 2005 (estimated)
- Study startSep 2005
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Venous InsufficiencyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 60 participants
Sponsor and investigators
- Lead sponsor
- Ortec International
- Sponsor type
- Industry (pharma, biotech, devices)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00270972
- Sponsor's protocol ID
- 100-VLU-02-CLN
- Status last verified
- Jun 2006
- First submitted
- 28 Dec 2005
- Last updated
- 5 Jun 2006
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Jun 2006. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Confirmatory Study to Evaluate the Safety and Efficacy of Cryopreserved Bilayered Cellular Matrix (ORCEL) for the Treatment of Venous Ulcers
- ClinicalTrials.gov ID
- NCT00270972
- Acronym / sponsor ID
- 100-VLU-02-CLN
- Conditions
- Venous Insufficiency, Leg Ulcer
- Keywords
- Venous leg ulcer, Venous insufficiency, OrCel
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 60 participants
- Lead sponsor
- Ortec InternationalIndustry (pharma, biotech, devices)
- Study start
- Sep 2005
- First posted
- 29 Dec 2005 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study was designed to confirm the clinical benefits and safety of OrCel in the treatment of venous ulcers. OrCel and standard care are compared to standard care alone. Standard care consists of currently accepted compression therapy.
Patients are treated for 12 weeks. Patients with healed ulcers are followed for an additional 12 weeks to assess durability of the healed wound.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Any race, between 18 and 85 years of age
- Male or female
- Chronic venous insufficiency
- Ulcer size between 2 and 20 sq cm, inclusive
- Ulcer present for at least one month
Key exclusion criteria (5 listed)
- Decrease in wound size >35% during Screening Phase
- Infection at ulcer site
- Uncontrolled diabetes mellitus
- Malnutrition
- Previous treatment with excluded medications
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Bilayered Cellular Matrix (OrCel) | Device | – |
Primary outcome
Investigator Assessment of wound healing
2 secondary outcomes
Planimetric assessment of wound healing
Photographic assessment of wound healing
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Jun 2006.
Related trials for Venous Insufficiency
Recruiting
DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
Venous Thromboembolism, Deep Venous Thrombosis
Not yet recruiting
Phenotyping Rehabilitation for Improving Frailty, Functional Capacity
Varicose Veins
Active, not recruitingPhase 1/2
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
Staphylococcus Aureus
Active, not recruiting
Comparison of the Effects of Kinesio Taping and Interval Exercise in Patients Diagnosed With Venous Insufficiency: A Randomised Controlled Trial
Chronic Venous Insufficiency C2 and Below
Recruiting
The GORE® VIABAHN® FORTEGRA Venous Stent Post-Approval Study
Venous Thromboses, Venous Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
10 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Bilayered Cellular Matrix (OrCel) in people with Venous Insufficiency and Leg Ulcer, run by Ortec International at 10 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 5 Jun 2006. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 10 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Investigator Assessment of wound healing. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jun 2006.